A — Agilent Technologies, Inc.

Agilent Technologies Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $1.8 billion, a core growth of 4.4% year-over-year, within November guidance range.
• Operating Margin: 24.6%, consistent with expectations; down 50 basis points year-over-year due to tariff expenses.
• Earnings Per Share (EPS): $1.36, a 4% increase; adjusted for a $10 million revenue impact from a winter storm, results would have exceeded guidance midpoints.
• Gross Margin: 53.7%, down 100 basis points year-over-year.
• Operating Cash Flow: $268 million; capital expenditures of $93 million; $152 million in share repurchases and $72 million in dividends paid.

2. Strategic Updates and Business Highlights

• Customer Intimacy: Focus on enterprise services has led to marquee wins with major pharma accounts, contributing to a low double-digit CAGR in services revenue.
• Product Innovations: Successful launches include the Altura ultra-inert column portfolio and Pro iQ LC/MS, with significant uptake and positive customer feedback.
• Ignite Operating System: Continued to drive operational excellence, pricing realization, and procurement savings, with plans for expansion into new value creation workstreams.
• End Market Performance: Strong growth in pharma (7%), particularly in biotech (double-digit growth), and advanced materials (20% growth). Environmental forensics remained flat, while food declined 4%.

3. Forward Guidance and Outlook

• Full Year Guidance: Maintaining core revenue growth expectations of 4% to 6% and EPS guidance of $5.90 to $6.04, reflecting a $0.04 increase due to favorable currency impacts.
• Q2 Expectations: Anticipating revenue of $1.79 billion to $1.82 billion (4% to 5.5% core growth) and EPS of $1.39 to $1.42 (7% growth at midpoint).
• Long-Term Growth Drivers: Continued focus on the instrument replacement cycle, GLP-1 growth, and expanding enterprise services.

4. Bad News, Challenges, or Points of Concern

• Weather Impact: A winter storm in late January caused a $10 million revenue impact, primarily affecting logistics and shipping.
• Softness in Academia and Government: Continued challenges in these sectors, leading to lower-than-expected performance in cell analysis and genomics.
• Tariff Headwinds: Ongoing tariff expenses impacted margins, although management expects to fully offset these through pricing and cost-saving measures.
• Market Uncertainty: Concerns regarding the macroeconomic environment and potential impacts on customer spending, particularly in small and mid-cap biotech sectors.

5. Notable Q&A Insights

• Weather Recovery: Majority of the $10 million revenue loss from the storm has been recouped, with modest margin impact.
• M&A Readiness: Management expressed confidence in their ability to integrate acquisitions effectively, leveraging the Ignite Operating System.
• Market Dynamics: Strong underlying momentum in key markets, with optimism about improving conditions in academia and government, though cautious spending persists.
• CDMO Business: Expected to grow mid-teens for the year, with visibility into larger commercial batches ramping up.
• China Growth: Anticipated mid- to high single-digit growth in China, with ongoing demand driven by semiconductor reshoring and innovation priorities.

Overall, Agilent Technologies demonstrated solid performance in Q1 2026, with strategic initiatives in customer intimacy and product innovation positioning the company for continued growth, despite facing some challenges in specific markets and external conditions.